<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Before any treatment of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> in accordance with the principles of evidence-based medicine can be generally recommended, the considerable disease <z:hpo ids='HP_0001425'>heterogeneity</z:hpo> must be taken into account, and randomized controlled intervention trials directed to cardiovascular and microangiopathic organ damage end points must be performed for the various subgroups of patients </plain></SENT>
<SENT sid="1" pm="."><plain>Until then, it appears prudent to treat the typical Caucasian type 2 diabetic patient primarily by nondrug therapies, and if they fail to achieve the patient's individual treatment goals, then insulin treatment should be initiated </plain></SENT>
<SENT sid="2" pm="."><plain>Treatment of type 2 diabetic patients with insulin alone, aimed at the patient's individual therapeutic goals, is effective and safe when conducted as an integral part of specific and structured treatment and teaching programs </plain></SENT>
<SENT sid="3" pm="."><plain>Insulin treatment can be safely used to achieve near-<z:mpath ids='MPATH_458'>normal</z:mpath> HbA1c levels (&lt; 7.0-7.5%) if prevention of <z:e sem="disease" ids="C0025945" disease_type="Disease or Syndrome" abbrv="">diabetic microangiopathy</z:e> is indicated, or to maintain HbA1c levels &lt; 8.5-9.0% if catabolic symptoms due to insulin deficiency are to be prevented </plain></SENT>
</text></document>